Activin and Inhibin

CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7.Form:Solid.

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection , with an IC 50 of 39 nM for CDK9/CycT1In VitroCDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication. MCE has not independently

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection , with an IC 50 of 39 nM for CDK9/CycT1In VitroCDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication. MCE has not independently

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection , with an IC 50 of 39 nM for CDK9/CycT1In VitroCDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication. MCE has not independently

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection , with an IC 50 of 39 nM for CDK9/CycT1In VitroCDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication. MCE has not independently

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection , with an IC 50 of 39 nM for CDK9/CycT1In VitroCDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication. MCE has not independently

CDK9-IN-2 is a special cyclin-dependent kinase 9 ( CDK9 ) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC 50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours),

CDK9-IN-2 is a special cyclin-dependent kinase 9 ( CDK9 ) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC 50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours),

CDK9-IN-2 is a special cyclin-dependent kinase 9 ( CDK9 ) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC 50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours),

CDK9-IN-2 is a special cyclin-dependent kinase 9 ( CDK9 ) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC 50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours),

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor ( IC 50 =11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM: CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor ( IC 50 =11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM: CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without